|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/07/21 Accolade, Inc. 10-K 2/28/21 103:10M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.55M
2: EX-4.6 Instrument Defining the Rights of Security Holders HTML 41K
3: EX-10.13 Material Contract HTML 62K
4: EX-21.1 Subsidiaries List HTML 29K
5: EX-23.1 Consent of Expert or Counsel HTML 28K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 31K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 31K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 30K
15: R1 Document and Entity Information HTML 93K
16: R2 Consolidated Balance Sheets HTML 119K
17: R3 Consolidated Balance Sheets (Parenthetical) HTML 52K
18: R4 Consolidated Statements of Operations HTML 75K
19: R5 Consolidated Statements of Convertible Preferred HTML 154K
Stock and Stockholders' Equity (Deficit)
20: R6 Consolidated Statements of Convertible Preferred HTML 31K
Stock and Stockholders' Equity (Deficit)
(Parenthetical)
21: R7 Consolidated Statements of Cash Flows HTML 133K
22: R8 Background HTML 36K
23: R9 Summary of Significant Accounting Policies HTML 113K
24: R10 Acquisition of MD Insider (Mdi) HTML 53K
25: R11 Property and Equipment HTML 50K
26: R12 Accrued Expenses and Accrued Compensation HTML 46K
27: R13 Fair Value Measurements HTML 67K
28: R14 Debt Facility HTML 49K
29: R15 Stockholders' Equity (Deficit) HTML 79K
30: R16 Stock Options and Warrants HTML 144K
31: R17 Defined Contribution Retirement Plan HTML 31K
32: R18 Income Taxes HTML 141K
33: R19 Net Loss Per Share Attributable to Common HTML 57K
Stockholders
34: R20 Commitments HTML 44K
35: R21 Change Healthcare Joint Development Agreement HTML 42K
36: R22 Related Party Transactions HTML 31K
37: R23 Subsequent Events HTML 36K
38: R24 Summary of Significant Accounting Policies HTML 166K
(Policies)
39: R25 Summary of Significant Accounting Policies HTML 69K
(Tables)
40: R26 Acquisition of MD Insider (Mdi) (Tables) HTML 52K
41: R27 Property and Equipment (Tables) HTML 48K
42: R28 Accrued Expenses and Accrued Compensation (Tables) HTML 43K
43: R29 Fair Value Measurements (Tables) HTML 65K
44: R30 Debt facility (Tables) HTML 36K
45: R31 Stockholders' Equity (Deficit) (Tables) HTML 70K
46: R32 Stock Options and Warrants (Tables) HTML 140K
47: R33 Income Taxes (Tables) HTML 139K
48: R34 Net Loss Per Share Attributable to Common HTML 58K
Stockholders (Tables)
49: R35 Commitments (Tables) HTML 39K
50: R36 Change Healthcare Joint Development Agreement HTML 37K
(Tables)
51: R37 Background - Initial Public Offering (Details) HTML 61K
52: R38 Summary of Significant Accounting Policies - HTML 40K
Useful lives for property and equipment (Details)
53: R39 Summary of Significant Accounting Policies - HTML 37K
Capitalized Internal-Use Software Costs (Details)
54: R40 Summary of Significant Accounting Policies - HTML 38K
Intangible Assets (Details)
55: R41 Summary of Significant Accounting Policies - HTML 43K
Revenue and Deferred Revenue (Details)
56: R42 Summary of Significant Accounting Policies - HTML 32K
Revenue and Deferred Revenue Narratives (Details)
57: R43 Summary of Significant Accounting Policies - Cost HTML 51K
to obtain and fulfill a contract (Details)
58: R44 Summary of Significant Accounting Policies - HTML 49K
Concentration of Credit Risk (Details)
59: R45 Summary of Significant Accounting Policies - HTML 41K
Additional Information (Details)
60: R46 Summary of Significant Accounting Policies - HTML 30K
Deferred Offering Costs (Details)
61: R47 Summary of Significant Accounting Policies - HTML 33K
Unaudited Pro Forma Financial Information -
(Details)
62: R48 Acquisition of MD Insider (MDI) - Summary of HTML 55K
Purchase Consideration (Details)
63: R49 Acquisition of MD Insider (MDI) - Summary of HTML 64K
Estimated Fair Values of Assets Acquired and
Liabilities Assumed (Details)
64: R50 Property and Equipment (Details) HTML 58K
65: R51 Accrued Expenses and Accrued Compensation HTML 42K
(Details)
66: R52 Accrued Expenses and Accrued Compensation - HTML 48K
Additional Information (Details)
67: R53 Fair Value Measurements (Details) HTML 39K
68: R54 Debt facility (Details) HTML 90K
69: R55 Debt facility - Long-Term Debt (Details) HTML 37K
70: R56 Debt facility - Warrant Rights (Details) HTML 79K
71: R57 Stockholders' Equity (Deficit) - Convertible HTML 83K
Preferred Stock (Details)
72: R58 Stockholders' Equity (Deficit) - Additional HTML 72K
Information (Details)
73: R59 Stockholders' Equity (Deficit) - Common Stock HTML 42K
(Details)
74: R60 Stock Options and Warrants - Shares (Details) HTML 69K
75: R61 Stock Options and Warrants - Compensation expense HTML 43K
(Details)
76: R62 Stock Options and Warrants - Fair value of common HTML 48K
stock (Details)
77: R63 Stock Options and Warrants - Award Option HTML 75K
(Details)
78: R64 Stock Options and Warrants - Restricted Stock HTML 63K
Units (Details)
79: R65 Stock Options and Warrants - Common Stock Warrants HTML 71K
(Details)
80: R66 Stock Options and Warrants - Common Stock Warrants HTML 37K
- Summary of activity - (Details)
81: R67 Stock Options and Warrants - Equity - (Details) HTML 51K
82: R68 Defined Contribution Retirement Plan - Additional HTML 38K
Information (Details)
83: R69 Income Taxes - Components of loss before income HTML 37K
taxes (Details)
84: R70 Income Taxes - Significant components of income HTML 48K
taxes (Details)
85: R71 Income Taxes - Reconciliation of income tax HTML 46K
expense at U.S. Federal statutory income tax rate
(Details)
86: R72 Income Taxes - Significant components of the HTML 57K
Company's deferred tax assets and liabilities
(Details)
87: R73 Income Taxes - Operating loss carryforwards HTML 40K
(Details)
88: R74 Income Taxes - Tax credit carryforwards (Details) HTML 31K
89: R75 Income Taxes - Changes in deferred tax, valuation HTML 34K
allowance (Details)
90: R76 Income Taxes - Additional Information (Details) HTML 33K
91: R77 Income Taxes - Tax Act (Details) HTML 30K
92: R78 Net Loss Per Share Attributable to Common HTML 41K
Stockholders (Details)
93: R79 Net Loss Per Share Attributable to Common HTML 39K
Stockholders - Stock Options (Details)
94: R80 Commitments - Future minimum lease payments HTML 57K
(Details)
95: R81 Commitments - Legal Proceedings (Details) HTML 38K
96: R82 Change Healthcare Joint Development Agreement HTML 59K
(Details)
97: R83 Change Healthcare Joint Development Agreement - HTML 40K
Future data license fee payments (Details)
98: R84 Related Party Transactions (Details) HTML 38K
99: R85 Subsequent Events (Details) HTML 76K
101: XML IDEA XML File -- Filing Summary XML 189K
14: XML XBRL Instance -- accd-20210228x10k_htm XML 2.23M
100: EXCEL IDEA Workbook of Financial Reports XLSX 125K
10: EX-101.CAL XBRL Calculations -- accd-20210228_cal XML 205K
11: EX-101.DEF XBRL Definitions -- accd-20210228_def XML 769K
12: EX-101.LAB XBRL Labels -- accd-20210228_lab XML 1.70M
13: EX-101.PRE XBRL Presentations -- accd-20210228_pre XML 1.30M
9: EX-101.SCH XBRL Schema -- accd-20210228 XSD 224K
102: JSON XBRL Instance as JSON Data -- MetaLinks 439± 688K
103: ZIP XBRL Zipped Folder -- 0001558370-21-006527-xbrl Zip 408K
Exhibit 21.1
Accolade, Inc.
Subsidiaries of the Registrant
The following is a list of the Company’s consolidating subsidiaries as of February 28, 2021.
Name of Subsidiary |
| State or Jurisdiction of Incorporation |
Accolade Techologies sro | | Czech Republic |
MD Insider, Inc. | | Delaware |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/7/21 | 4 | ||
| For Period end: | 2/28/21 | 5 | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/26/24 Accolade, Inc. S-8 4/26/24 4:141K 4/26/24 Accolade, Inc. 10-K 2/29/24 98:9.3M 4/28/23 Accolade, Inc. 10-K 2/28/23 103:11M Toppan Merrill Bridge/FA 4/28/23 Accolade, Inc. S-8 4/28/23 4:90K Toppan Merrill/FA 6/03/22 Accolade, Inc. S-8 6/03/22 4:87K Toppan Merrill/FA 5/02/22 Accolade, Inc. 10-K 2/28/22 102:12M Toppan Merrill Bridge/FA 7/09/21 Accolade, Inc. S-3ASR 7/09/21 7:1.3M Toppan Merrill/FA 7/08/21 Accolade, Inc. 10-Q 5/31/21 67:6.9M Toppan Merrill Bridge/FA 6/10/21 Accolade, Inc. S-8 6/10/21 5:564K Toppan Merrill/FA 5/11/21 Accolade, Inc. POS AM 2:707K Toppan Merrill/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/01/21 Accolade, Inc. S-1/A 4:3.7M Toppan Merrill/FA 3/29/21 Accolade, Inc. 8-K:1,2,3,8 3/23/21 14:1.3M Toppan Merrill/FA 3/15/21 Accolade, Inc. S-1 143:13M Toppan Merrill/FA 3/04/21 Accolade, Inc. 8-K:1,3,8,9 3/03/21 13:1.5M Toppan Merrill/FA 11/09/20 Accolade, Inc. 8-K:1,9 11/06/20 11:245K Toppan Merrill/FA 10/14/20 Accolade, Inc. 10-Q 8/31/20 64:5.9M Toppan Merrill Bridge/FA 8/25/20 Accolade, Inc. 8-K:1,9 8/21/20 11:269K Toppan Merrill Bridge/FA 7/10/20 Accolade, Inc. 8-K:5,9 7/07/20 2:58K Toppan Merrill/FA 6/24/20 Accolade, Inc. S-1/A 5:5.7M Toppan Merrill-FA 6/16/20 Accolade, Inc. S-1/A 10:7.8M Toppan Merrill-FA 2/28/20 Accolade, Inc. S-1 39:24M Toppan Merrill-FA |